Baylor College of Medicine
Houston, Texas, 77030, United States
Location status: Recruiting
Location contact
Lynnette A. Averill, Ph.D.
PRINCIPAL_INVESTIGATOR
Marika Del Motte, M.Sc.
CONTACT
NCT Number: NCT06888128
The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.
Interested in participating?
Request Info21 year–64 year
All sexes
Interventional
Phase 2
Houston, Texas, 77030, United States
Location status: Recruiting
Lynnette A. Averill, Ph.D.
PRINCIPAL_INVESTIGATOR
Marika Del Motte, M.Sc.
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant.
The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session.
Time frame: Baseline to 6-month follow up
Safety as measured by Adverse Event Reporting
Time frame: Baseline to 6-month follow up
Safety as measured by changes in suicidal ideation on the Columbia Suicide Safety Rating Scale (CSSRS). This section of the measure is assessed on a scale of 0 to 25, with higher scores indicating greater intensity of suicidal ideation.
Time frame: Baseline to 6-month follow up
Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms.
Time frame: Baseline to 6-month follow up
Change in self-reported PTSD Checklist 5 (PCL-5) scores. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms.
Time frame: Baseline to 6-month follow up
Changes in self-reported Quick Inventory of Depression Severity (QIDS) scores. This measure is assessed on a scale of 0 to 27, with higher scores reflecting increased severity of depressive symptoms.
Time frame: Baseline to 6-month follow up
Changes in self-reported Generalized Anxiety Disorder-7 (GAD-7) scores. This measure is assessed on a scale of 0 to 21, with higher scores reflecting increased severity of anxiety symptoms.
Time frame: Baseline to 6-month follow up
The effect of psilocybin-assisted therapy on functional connectivity networks using resting-state functional magnetic resonance imaging (MRI)
Contact information is provided by the study sponsor or research team.
Baylor College of Medicine
Other
The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma
Acronym: STARLIGHT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06776523
Common Mental Health Problems, Mental Disorders
Zurich, Switzerland
View Trial DetailsNCT06900712
Behavior, Behavioral Symptoms
Cleveland, Ohio, United States
View Trial DetailsNCT06956781
Hematologic Diseases, Hemic and Lymphatic Diseases
Rochester, New York, United States
View Trial DetailsNCT07419594
Intrusion, Intrusion Symptom
Berlin, State of Berlin, Germany
View Trial Details